MA55982A - Composition pharmaceutique pour le traitement de tumeurs - Google Patents

Composition pharmaceutique pour le traitement de tumeurs

Info

Publication number
MA55982A
MA55982A MA055982A MA55982A MA55982A MA 55982 A MA55982 A MA 55982A MA 055982 A MA055982 A MA 055982A MA 55982 A MA55982 A MA 55982A MA 55982 A MA55982 A MA 55982A
Authority
MA
Morocco
Prior art keywords
tumors
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
MA055982A
Other languages
English (en)
Inventor
Yasuhiro Funahashi
Taro Semba
Takuya Suzuki
Original Assignee
Eisai R&D Man Co Ltd
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Ono Pharmaceutical Co filed Critical Eisai R&D Man Co Ltd
Publication of MA55982A publication Critical patent/MA55982A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055982A 2019-07-26 2020-07-27 Composition pharmaceutique pour le traitement de tumeurs MA55982A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019138041 2019-07-26
US16/835,719 US11083705B2 (en) 2019-07-26 2020-03-31 Pharmaceutical composition for treating tumor

Publications (1)

Publication Number Publication Date
MA55982A true MA55982A (fr) 2022-03-23

Family

ID=74187564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055982A MA55982A (fr) 2019-07-26 2020-07-27 Composition pharmaceutique pour le traitement de tumeurs

Country Status (15)

Country Link
US (2) US11083705B2 (fr)
EP (1) EP3970745A4 (fr)
JP (1) JP7649742B2 (fr)
KR (1) KR20220041044A (fr)
CN (1) CN113993545A (fr)
AU (1) AU2020323402A1 (fr)
BR (1) BR112021026170A2 (fr)
CA (1) CA3143486A1 (fr)
IL (1) IL289213A (fr)
MA (1) MA55982A (fr)
MX (1) MX2021016093A (fr)
PH (1) PH12021553177A1 (fr)
TW (4) TWI904982B (fr)
WO (1) WO2021020336A1 (fr)
ZA (1) ZA202110686B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2415470T1 (sl) 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposomski sestavek
EP3449921B1 (fr) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin pour l' inhibition de croissance tumorale
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN116407492B (zh) * 2021-12-29 2024-11-05 北京新领先医药科技发展有限公司 一种甲磺酸艾日布林注射液组合物及制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5551683B2 (fr) 1972-10-23 1980-12-25
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
ATE227979T1 (de) 1993-04-22 2002-12-15 Skyepharma Inc Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
FR2736056B1 (fr) 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
IL139960A0 (en) 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
DE60222580T2 (de) 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
EP2206517B1 (fr) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes contenant un anticorps anti-PD-L1
DE10255106A1 (de) 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
CA2506749A1 (fr) 2002-11-26 2004-06-10 Gilead Sciences, Inc. Procede de chargement de medicaments dans des liposomes par gradient
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
BR0317882A (pt) 2002-12-31 2005-12-13 Bharat Serums & Vaccines Ltd Processo para fabricação de lipossomas de longa circulação não tratados com peg; lipossoma; composição de doxorrubicina lipossomal de longa duração não tratada com peg; e método
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20070112176A1 (en) 2003-04-04 2007-05-17 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structure containing anti-mt-mmp monoclonal antibody
US6747011B1 (en) 2003-06-04 2004-06-08 A.P. Group, Inc. Antitumor drugs and methods
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
JPWO2005073223A1 (ja) 2004-01-29 2007-09-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 マクロライド系化合物の安定化方法
UA86063C2 (ru) 2004-05-03 2009-03-25 Хермес Біосайенсез, Інк. Липосомы для снабжения лекарств
DE602005018043D1 (de) 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CN101899026B (zh) 2004-06-03 2016-08-03 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
CA2582949A1 (fr) 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes permettant une meilleure retention du medicament, destines au traitement du cancer
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2008141276A1 (fr) 2007-05-11 2008-11-20 Centocor, Inc. Composition, procédés et utilisations d'immunoliposome anti-alpha-v
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
US20090196918A1 (en) 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
EP2328920A2 (fr) 2008-08-25 2011-06-08 Amplimmune, Inc. Polypeptides co-stimulateurs ciblés et leurs procédés d'utilisation dans le traitement du cancer
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
JP5622719B2 (ja) 2009-03-30 2014-11-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
SI2415470T1 (sl) 2009-03-30 2016-12-30 Eisai R&D Management Co., Ltd. Liposomski sestavek
JP5388735B2 (ja) 2009-07-21 2014-01-15 浜松ホトニクス株式会社 マイクロチャンネルプレート
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
BR112012018232B8 (pt) 2010-01-26 2023-01-10 Eisai R&D Man Co Ltd Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
ES2731653T3 (es) 2011-03-18 2019-11-18 Eisai R&D Man Co Ltd Métodos y usos para predecir la respuesta a la eribulina
CA2830806C (fr) 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Formulations stables d'anticorps diriges contre le recepteur humain pd-1 de la mort programmee et traitements associes
EP2693875A4 (fr) 2011-04-08 2014-10-22 British Columbia Cancer Agency Composés de bisphénol et leurs procédés d'utilisation
CN103917224A (zh) 2011-07-19 2014-07-09 Stc·Unm公司 基于在癌症的炎症环境释放治疗性负载的腹膜内给药的纳米载体
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
WO2014087230A1 (fr) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Utilisation d'éribuline dans le traitement de cancer du sein
SMT201700530T1 (it) 2013-03-14 2018-01-11 Bristol Myers Squibb Co Combinazione di agonista di dr5 e antagonista anti-pd-1 e metodi d'uso
JP6720075B2 (ja) 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
ES2705698T3 (es) 2013-06-26 2019-03-26 Eisai R&D Man Co Ltd Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib
EP3046543A1 (fr) 2013-09-18 2016-07-27 Stc.Unm Nanoparticules de silice mésoporeuse toroïdales (tmsnp) et proto-cellules associées
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US20170020817A1 (en) 2013-12-19 2017-01-26 Luminus Biosciences, Inc. Solid nanoparticle formulation of microtuble inhibitors with reduced ostwald repening for oral administration
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
SG11201607298QA (en) 2014-03-03 2016-09-29 Eisai R&D Man Co Ltd Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer
EP3114144A1 (fr) * 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Traitement du cancer du rein à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
CN105640935A (zh) 2014-11-12 2016-06-08 天津市汉康医药生物技术有限公司 供注射用甲磺酸艾日布林药物组合物
JP6951248B2 (ja) * 2015-03-04 2021-10-20 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
EP3449921B1 (fr) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin pour l' inhibition de croissance tumorale
JP2019530706A (ja) * 2016-10-14 2019-10-24 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 尿路上皮がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control

Also Published As

Publication number Publication date
EP3970745A1 (fr) 2022-03-23
IL289213A (en) 2022-02-01
TWI904981B (zh) 2025-11-11
PH12021553177A1 (en) 2022-11-07
CN113993545A (zh) 2022-01-28
US11083705B2 (en) 2021-08-10
ZA202110686B (en) 2022-09-28
TW202118486A (zh) 2021-05-16
US20210177802A1 (en) 2021-06-17
TW202515533A (zh) 2025-04-16
JPWO2021020336A1 (fr) 2021-02-04
MX2021016093A (es) 2022-02-03
US20210023047A1 (en) 2021-01-28
AU2020323402A1 (en) 2022-01-27
TWI904983B (zh) 2025-11-11
CA3143486A1 (fr) 2021-02-04
TW202515534A (zh) 2025-04-16
NZ783713A (en) 2025-06-27
TWI904982B (zh) 2025-11-11
EP3970745A4 (fr) 2023-07-19
TWI865566B (zh) 2024-12-11
WO2021020336A1 (fr) 2021-02-04
BR112021026170A2 (pt) 2022-02-15
TW202515532A (zh) 2025-04-16
JP7649742B2 (ja) 2025-03-21
KR20220041044A (ko) 2022-03-31

Similar Documents

Publication Publication Date Title
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
EP3222278C0 (fr) Utilisation de l'azelnidipine pour la préparation d'une composition pharmaceutique indiquée pour le traitement du cancer
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3533466A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
EP3946357A4 (fr) Formulations topiques pour le traitement de neuropathies périphériques
EP3766497A4 (fr) Médicament pour le traitement de la toux
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3378484A4 (fr) Composition pharmaceutique pour le traitement de la fibrose cardiaque
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
EP3898991A4 (fr) Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP3400942A4 (fr) Utilisation de dérivés de quinoléine pour le traitement du cancer de l' sophage et procédé de traitement, composition pharmaceutique et trousse associée
EP4209216A4 (fr) Composition pharmaceutique pour le traitement de tumeurs
EP4081201A4 (fr) Composition pharmaceutique pour le traitement ou la prévention de nombreux troubles inflammatoires
EP3329929A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la sécheresse oculaire
EP3827831A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la stéatohépatite non alcoolique
EP3990458A4 (fr) Composés pour le traitement du cancer
EP3793548A4 (fr) Composés pour le traitement du cancer du pancréas
EP3858351A4 (fr) Composition pharmaceutique pour le traitement de la fibrose
EP3632447A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie osseuse
EP4174087A4 (fr) Médicament pour le traitement de tumeur
EP3437655A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer